MONTREAL, June 02, 2025 (GLOBE NEWSWIRE) -- Ghislain Houle, Executive Vice-President and Chief Financial Officer of CN (TSX: CNR) (NYSE: CNI), will address the Wells Fargo 2025 Industrials and Materials Conference on June 11, 2025, at 9:00 a.m. Eastern Time (ET). CN will provide a live webcast via the Investors section of its website at www.cn.ca/investors. A replay of the webcast will be available following the event. About CNCN powers the economy by safely transporting more than 300 million tons of natura ...

CALGARY, Alberta, June 02, 2025 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) is pleased to announce the appointment of Shaina Morihira as its Chief Financial Officer, effective June 4, 2025. Ms. Morihira will succeed David Hendry who, as previously announced, is retiring. Shaina brings more than 20 years of experience in the energy industry, with the past nine years spent at Enerplus Corporation. In her most recent role as Vice President, Finance, she led the treasury, cor ...

– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared to placebo, with a safety and tolerability profile similar to placebo – The FDA grants Priority Review designation for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition1 COPENHAGEN, ...

ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited (together, Hetero USA). This agreement resolves the patent litigation brought by Esperion against Hetero USA in response to Hetero USA’ s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration ...

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new ...

CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Crawford United Corporation (OTC: CRAWA) announced today that contemporaneously with this press release it has posted investor presentation materials containing supplemental information for investors and other interested parties on the company’s website. The company may refer to this information in discussions it has with investors from time to time. The investor presentation will be posted to https://crawfordunited.com/investor.html. The information contained i ...

Somerset, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in AI-driven healthcare technology solutions for medical practices and health systems nationwide, announced today that its Co-Chief Executive Officers have been invited to participate in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow,” presented by Maxim Group LLC. The Healthcare IT Panel, featuring CareCloud, will take place on Tuesday, June 3, 202 ...

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX:CAR.UN) announced today that it is planning to invest in two infill development projects for the construction of an estimated 120 residential rental suites on excess land in Mississauga, Ontario (the “GTA Development Projects”). Additionally, CAPREIT is underway with the conversion of certain underutilized non-residential spaces identified throughout its current apartment portfolio for the ...

Core Insights - Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing systemic oncolytic targeted immunotherapies, with its lead candidate CLD-401 presented at the ASCO Annual Meeting [1][2] Group 1: Technology and Innovation - Calidi has developed an enveloped form of its proprietary oncolytic virus that shows greater resistance to immune clearance, enhancing systemic delivery and efficacy in pre-clinical models [2] - The novel genetic modification in CLD-401 incorporates a chimeric CD55 receptor into the virus envelope, which inhibits complement-mediated clearance, improving the virus's stability in circulation [2][4] - The RedTail platform allows for the delivery of genetic payloads directly into the tumor microenvironment, with CLD-401 expressing an IL-15 superagonist to activate and expand natural killer (NK) cells and CD8+ T cells [3][4] Group 2: Strategic Development - Calidi is conducting IND-enabling studies for CLD-401 and plans to submit an Investigational New Drug (IND) application in the second half of 2026 [4] - The company is actively seeking strategic partnerships to accelerate clinical development and enhance the impact of its RedTail platform [4][6] - The lead candidate targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs [7]

LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) -- Bitmine Immersion Technologies, Inc. (OTCQX: BMNRD) (“Bitmine” or “Company”), a technology company focused on Bitcoin mining using immersion technology, today announced that it expects its shares of common stock to be approved for listing on the NYSE American LLC stock exchange (“NYSE American”). The Company expects that its common stock will begin trading on the NYSE American under the symbol, “BMNR,” at the opening of trading on or about June 5, 2025, subject t ...